Altrip 6.25 mg Tablet, 1 strip
Altrip 6.25 mg Tablet, 1 stripDescription:Almotriptan is a selective and potent serotonin (5-HT1B/1D) agonist. Almotriptan binds to specific serotonin receptors on meningeal arteries inhibiting the release of vasoactive peptides and causing constriction of the arteries. It has a limited effect on arteries supplying blood to the brain and little effect on cardiac and pulmonary vessels.ndicationAlmotriptan is prescribed to treat the acute headache phase of migraine attacks with or without aura. Almotriptan is the only oral triptan approved in the USA for the treatment of migraine in adolescent from 12 to 17 years of age.Dosage & AdministrationAcute Treatment of Migraine Attacks: The recommended dose of Altrip in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. If the headache is relieved after the initial Altrip (almotriptan malate) dose but returns, the dose may be repeated after 2 hours. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.Hepatic Impairment:The recommended starting dose of almotriptan malate in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour periodRenal Impairment:The recommended starting dose of almotriptan malate in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour periodContraindicationAs with other 5-HT1B/1D receptor agonists, almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetals angina) or severe hypertension and uncontrolled mild or moderate hypertension. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated.PrecautionHypersensitivity to the active substance or to any of the excipients. Patients with severe hepatic impairment, with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA) Peripheral vascular diseaseSide EffectsSerious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan malate Tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD (Coronary Artery Disease).Drug InteractionThese drugs have been reported to cause prolonged vasospastic reactions. Cases of life-threatening serotonin syndrome have been reported during combined use of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).OverdoseNo case of overdose has been reported. The most frequently reported adverse event in patients receiving 150 mg (the highest dose administered to patients) was somnolence.Pregnancy & LactationPregnancy Category C. There is no data regarding excretion of almotriptan in human milk.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.250.80/=
Arotril 0.5mg Tab
Arotril (Clonazepam), a derivative of benzodiazepine is mainly used as anticonvulsant drug. Clonazepam brings about direct inhibition of cortical and sub-cortical epileptogenic focus and thus prevents the formation of convulsive activity. It displays several pharmacological properties, which are characteristics of benzodiazepine class of drugs. At the spinal cord level clonazepam depresses more reflux pathways and potentiates presynaptic inhibition of GABA in the CNS. Overcompensatory excitation processes are thereby reduced via negative feedback without substantiation of other physiologic neuronal activity...
Tk.6.00/=
Arotril 1mg Tab
Arotril (Clonazepam), a derivative of benzodiazepine is mainly used as anticonvulsant drug. Clonazepam brings about direct inhibition of cortical and sub-cortical epileptogenic focus and thus prevents the formation of convulsive activity. It displays several pharmacological properties, which are characteristics of benzodiazepine class of drugs. At the spinal cord level clonazepam depresses more reflux pathways and potentiates presynaptic inhibition of GABA in the CNS. Overcompensatory excitation processes are thereby reduced via negative feedback without substantiation of other physiologic neuronal activity...
Tk.6.00/=
Arotril 2mg Tab
Arotril (Clonazepam), a derivative of benzodiazepine is mainly used as anticonvulsant drug. Clonazepam brings about direct inhibition of cortical and sub-cortical epileptogenic focus and thus prevents the formation of convulsive activity. It displays several pharmacological properties, which are characteristics of benzodiazepine class of drugs. At the spinal cord level clonazepam depresses more reflux pathways and potentiates presynaptic inhibition of GABA in the CNS. Overcompensatory excitation processes are thereby reduced via negative feedback without substantiation of other physiologic neuronal activity...
Tk.7.00/=
Disopan 1mg Inj
Disopan 1mg InjDescriptionChemically, clonazepam is a benzodiazepine derivative. It exhibits several pharmacologic properties, which are characteristics of the benzodiazepine class of drugs. In human it is capable of suppressing the spike and wave discharge in absence seizure (petit mal) and decreasing the frequency, amplitude, duration and spread of discharge in minor motor seizure.IndicationsTablet:• Anxiety disorders (Generalized, Phobic & Panic disorders)• Insomnia and sleep disturbances• Labile arterial hypertension• Peri and Post menopausal anxiety (Anxiety in middle aged women)• Burning Mouth Syndrome• Peri and Post menopausal anxiety (Anxiety in middle aged women)• Postoperative anxiety disorder• Post traumatic stress disorder• Anxiety in cancer patient (palliative treatment)• Tension Headache• Restless legs syndrome (RLS) or Wittmaack–Ekbom syndrome• Nocturnal myoclonus• Tourette's syndrome• Bipolar affective disorder• Resistant depression• Drug-induced dyskinesia• Choreiform movement• Fulgurant pain• Trigeminal neuralgia• EpilespsyInjection:• Epilepsy• Status epilepticus• Myoclonic seizure• Typical and atypical absences (Lennox-Gastaut syndrome)• Infantile spasm• Tonic-clonic seizure• Partial seizure• Absence seizure• Focal seizureDosage & AdministrationTablet:Infants and childrenInitial dose: 0.01 - 0.03 mg/kg/day. Up to 1 year: 0.25 mg daily in divided dose, not to exceed 0.05 mg/kg/days increase gradually to 0.5 - 1 mg.Increment dose: not more than 0.25 - 0.5 mg 1 - 5 years: 0.25 mg daily in divided dose, at intervals of 3 days increase to 1 - 3 mg.Maintenance dose: 0.1 - 0.2 mg/kg/day. 5 - 12 years: 0.5 mg daily in divided dose,Dosing interval: b.i.d. / t.i.d. increase to 3 - 6 mg.Adults and elderlyInitial dose: 1 mg daily in divided dose (Elderly 0.5 mg), not to exceed 1.5 mg/dayIncrement dose: 0.5 - 1 mg at intervals of 3 daysMaintenance dose: 4 - 8 mg/dayMaximum dose: 20 mg/day should be administered with cautionDosing interval: b.i.d. / t.i.d.Initial dose should be low and increased gradually to a maintenance dose that controls seizure without toxic effects. During discontinuation, the dose should be tapered.Injection:Infants and children: half of a vial (0.5 mg) by slow IV injection or by IV infusion. Adults: 1 vial (1 mg) by slow IV injection or by IV infusion. This dose can be repeated as required (1 - 4 mg are usually sufficient to reverse the status). In adults, the rate of injection must not exceed 0.25 - 0.5 mg per minute (0.5 – 1.0 mL of the prepared solution) and a total dose of 10 mg should not be exceeded.Slow intravenous injection: The contents of the vial must be diluted with 1 mL of water for injection prior to administration so as to avoid local irritation of the veins. The injection solution should be prepared immediately before use. IV injection should be administered slowly with continuous monitoring of EEG, respiration and blood pressure.Intravenous infusion: Clonazepam (the vial) can be diluted for infusion in a ratio of 1 vial (1 mg) to at least 85 mL diluting media. The diluting media can be any of the following: sodium chloride 0.9%; sodium chloride 0.45% + glucose 2.5%; glucose 5% or glucose 10%. These mixtures are stable for 24 hours at room temperature. Infusion bags other than PVC should be used for infusing Clonazepam. If PVC infusion bags are used then the mixture should be infused immediately or within 4 hours. The infusion time should not exceed 8 hours. Do not prepare Clonazepam infusions using sodium bicarbonate solution, as precipitation of the solution may occur.Intramuscular injection: The IM route should be used only in exceptional cases or if IV administration is not feasible.Side EffectsTablet:The most frequently occurring side effects of clonazepam are referable to CNS depression, drowsiness, fatigue, dizziness, muscle hypotonia, co-ordination disturbance, hypersalivation in infants, paradoxical aggression, irritability and mental change.Injection:Some side effects, like: fatigue, muscle weakness, dizziness, somnolence, light-headedness, ataxia, restlessness, hypersalivation in infants, paradoxical aggression, reduced co-ordination may occur with Clonazepam therapy but these effects are transient and generally disappears in the course of the treatment. Respiratory depression may occur in patients with pre-existing airways obstruction, or brain damage, or if other medications which depress respiration have been given. As a rule, this effect can be avoided by careful adjustment of the dose to individual requirements.PrecautionsTablet:When used in patients in whom several different types of seizure disorders coexist, clonazepam may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). This may require the addition of appropriate anticonvulsants or an increase in their dosages. The concomitant use of valproic acid and clonazepam may produce absence status. Periodic blood counts and liver function tests ..
Tk.150.00/=
Disopan 1mg tab
Disopan 1mg tabDescriptionChemically, clonazepam is a benzodiazepine derivative. It exhibits several pharmacologic properties, which are characteristics of the benzodiazepine class of drugs. In human it is capable of suppressing the spike and wave discharge in absence seizure (petit mal) and decreasing the frequency, amplitude, duration and spread of discharge in minor motor seizure.IndicationsTablet:• Anxiety disorders (Generalized, Phobic & Panic disorders)• Insomnia and sleep disturbances• Labile arterial hypertension• Peri and Post menopausal anxiety (Anxiety in middle aged women)• Burning Mouth Syndrome• Peri and Post menopausal anxiety (Anxiety in middle aged women)• Postoperative anxiety disorder• Post traumatic stress disorder• Anxiety in cancer patient (palliative treatment)• Tension Headache• Restless legs syndrome (RLS) or Wittmaack–Ekbom syndrome• Nocturnal myoclonus• Tourette's syndrome• Bipolar affective disorder• Resistant depression• Drug-induced dyskinesia• Choreiform movement• Fulgurant pain• Trigeminal neuralgia• EpilespsyInjection:• Epilepsy• Status epilepticus• Myoclonic seizure• Typical and atypical absences (Lennox-Gastaut syndrome)• Infantile spasm• Tonic-clonic seizure• Partial seizure• Absence seizure• Focal seizureDosage & AdministrationTablet:Infants and childrenInitial dose: 0.01 - 0.03 mg/kg/day. Up to 1 year: 0.25 mg daily in divided dose, not to exceed 0.05 mg/kg/days increase gradually to 0.5 - 1 mg.Increment dose: not more than 0.25 - 0.5 mg 1 - 5 years: 0.25 mg daily in divided dose, at intervals of 3 days increase to 1 - 3 mg.Maintenance dose: 0.1 - 0.2 mg/kg/day. 5 - 12 years: 0.5 mg daily in divided dose,Dosing interval: b.i.d. / t.i.d. increase to 3 - 6 mg.Adults and elderlyInitial dose: 1 mg daily in divided dose (Elderly 0.5 mg), not to exceed 1.5 mg/dayIncrement dose: 0.5 - 1 mg at intervals of 3 daysMaintenance dose: 4 - 8 mg/dayMaximum dose: 20 mg/day should be administered with cautionDosing interval: b.i.d. / t.i.d.Initial dose should be low and increased gradually to a maintenance dose that controls seizure without toxic effects. During discontinuation, the dose should be tapered.Injection:Infants and children: half of a vial (0.5 mg) by slow IV injection or by IV infusion. Adults: 1 vial (1 mg) by slow IV injection or by IV infusion. This dose can be repeated as required (1 - 4 mg are usually sufficient to reverse the status). In adults, the rate of injection must not exceed 0.25 - 0.5 mg per minute (0.5 – 1.0 mL of the prepared solution) and a total dose of 10 mg should not be exceeded.Slow intravenous injection: The contents of the vial must be diluted with 1 mL of water for injection prior to administration so as to avoid local irritation of the veins. The injection solution should be prepared immediately before use. IV injection should be administered slowly with continuous monitoring of EEG, respiration and blood pressure.Intravenous infusion: Clonazepam (the vial) can be diluted for infusion in a ratio of 1 vial (1 mg) to at least 85 mL diluting media. The diluting media can be any of the following: sodium chloride 0.9%; sodium chloride 0.45% + glucose 2.5%; glucose 5% or glucose 10%. These mixtures are stable for 24 hours at room temperature. Infusion bags other than PVC should be used for infusing Clonazepam. If PVC infusion bags are used then the mixture should be infused immediately or within 4 hours. The infusion time should not exceed 8 hours. Do not prepare Clonazepam infusions using sodium bicarbonate solution, as precipitation of the solution may occur.Intramuscular injection: The IM route should be used only in exceptional cases or if IV administration is not feasible.Side EffectsTablet:The most frequently occurring side effects of clonazepam are referable to CNS depression, drowsiness, fatigue, dizziness, muscle hypotonia, co-ordination disturbance, hypersalivation in infants, paradoxical aggression, irritability and mental change.Injection:Some side effects, like: fatigue, muscle weakness, dizziness, somnolence, light-headedness, ataxia, restlessness, hypersalivation in infants, paradoxical aggression, reduced co-ordination may occur with Clonazepam therapy but these effects are transient and generally disappears in the course of the treatment. Respiratory depression may occur in patients with pre-existing airways obstruction, or brain damage, or if other medications which depress respiration have been given. As a rule, this effect can be avoided by careful adjustment of the dose to individual requirements.PrecautionsTablet:When used in patients in whom several different types of seizure disorders coexist, clonazepam may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). This may require the addition of appropriate anticonvulsants or an increase in their dosages. The concomitant use of valproic acid and clonazepam may produce absence status. Periodic blood counts and liver function tests ..
Tk.9.00/=
Epitra 0.5 mg Tablet
Indication: Anxiety as well as panic disorder, with or without agoraphobia. Epilepsy and other seizure disorders. Alone or as an adjunct in the management of myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut syndrome). May also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides. Dosage & Administration:Dosage must be determined in each patient according to clinical response and tolerance. Children: The initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day and should not exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by not more than 0.25 to 0.50 mg every third day until a maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the larger dose should be given before retiring. Adults :1 mg (elderly 500 micrograms) initially at night for 4 nights, increased according to response over 2-4 weeks to usual maintenance dose of 4-8 mg usually at night (may be given in 3-4 divided doses if necessary). Dosage may be increased in increments of 0.5 to 1 mg every three days until seizures are adequately controlled...
Tk.6.90/=
Epitra 1 mg Tablet
Indication: Anxiety as well as panic disorder, with or without agoraphobia. Epilepsy and other seizure disorders. Alone or as an adjunct in the management of myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut syndrome). May also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides. Dosage & Administration:Dosage must be determined in each patient according to clinical response and tolerance. Children: The initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day and should not exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by not more than 0.25 to 0.50 mg every third day until a maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the larger dose should be given before retiring. Adults :1 mg (elderly 500 micrograms) initially at night for 4 nights, increased according to response over 2-4 weeks to usual maintenance dose of 4-8 mg usually at night (may be given in 3-4 divided doses if necessary). Dosage may be increased in increments of 0.5 to 1 mg every three days until seizures are adequately controlled...
Tk.8.00/=
Epitra 2 mg Tablet
Indication: Anxiety as well as panic disorder, with or without agoraphobia. Epilepsy and other seizure disorders. Alone or as an adjunct in the management of myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut syndrome). May also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides. Dosage & Administration:Dosage must be determined in each patient according to clinical response and tolerance. Children: The initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day and should not exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by not more than 0.25 to 0.50 mg every third day until a maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the larger dose should be given before retiring. Adults :1 mg (elderly 500 micrograms) initially at night for 4 nights, increased according to response over 2-4 weeks to usual maintenance dose of 4-8 mg usually at night (may be given in 3-4 divided doses if necessary). Dosage may be increased in increments of 0.5 to 1 mg every three days until seizures are adequately controlled...
Tk.11.00/=
Epitra Drops
Indication: Anxiety as well as panic disorder, with or without agoraphobia. Epilepsy and other seizure disorders. Alone or as an adjunct in the management of myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut syndrome). May also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides. Dosage & Administration:Dosage must be determined in each patient according to clinical response and tolerance. Children: The initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day and should not exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by not more than 0.25 to 0.50 mg every third day until a maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the larger dose should be given before retiring. Adults :1 mg (elderly 500 micrograms) initially at night for 4 nights, increased according to response over 2-4 weeks to usual maintenance dose of 4-8 mg usually at night (may be given in 3-4 divided doses if necessary). Dosage may be increased in increments of 0.5 to 1 mg every three days until seizures are adequately controlled...
Tk.80.55/=
Leptic 0.5 mg Tablet
Leptic 0.5 mg TabletDescriptionLeptic(Clonazepam) is available as scored tablets containing 0.5 mg, 1 mg & 2 mg Clonazepam USP. Chemically, Clonazepam is a benzodiazepine derivative. It exhibits several pharmacologic properties, which are characteristics of the benzodiazepine class of drugs. In human it is capable of suppressing the spike and wave discharge in absence seizure (petit mal) and decreasing the frequency, amplitude, duration and spread of discharge in minor motor seizure.CompositionLeptic0.5 : Each tablet contains Clonazepam USP 0.5 mg.Leptic1 : Each tablet contains Clonazepam USP 1 mg.Leptic2 : Each tablet contains Clonazepam USP 2 mg.Indications All clinical forms of epileptic disease & seizures in infants, children & adults, especially absence seizures including : atypical absence primary & secondarily generalized tonic-clonic (grand mal) tonic-clonic seizures partial (focal) seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus & associated abnormal movements Panic disorder with or without agoraphobiaDosage and administrationInfants and children Initial dosage : 0.01 - 0.03 mg/kg/day not to exceed 0.05 mg/kg/day Increment dosage : not more than 0.25 - 0.5 mg at intervals of 3 days Maintenance dosage : 0.1-0.2 mg/kg/day Dosing interval: b.i.d./ t.i.d. Up to 1 year: 0.25 mg daily in divided dose, increase gradually to 0.5 - 1 mg. 1-5 years : 0.25 mg daily in divided dose, increase to 1-3 mg 5-12 years : 0.5 mg daily in divided dose increase to 3-6 mg. Adults and elderly Initial dosage: 1 mg daily in divided dose (Elderly 0.5 mg), not to exceed 1.5 mg/day Increment dosage : 0.5 - 1 mg at intervals of 3 days Maintenance dosage : 4 - 8 mg/day Maximum dosage : 20 mg/day should be administered with caution Dosing interval : b.i.d./t.i.d. Initial dosage should be low and increased gradually to a maintenance dosage that controls seizure without toxic effects.During discontinuation, the dosage should be tapered. Side effectsThe most frequently occurring side effects of Clonazepam are referable to CNS depression, drowsiness, fatigue, dizziness, muscle hypotonia, co-ordination disturbance, hypersalivation in infants, paradoxical aggression, irritability and mental change.Use in pregnancy and lactationThe use of Clonazepam during pregnancy or lactation should be avoided. Clonazepam is excreted into the breast milk and should therefore be avoided in breast-feeding mothers.PrecautionsWhen used in patients in whom several different types of seizure disorders co-exist, Clonazepam may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). This may require the addition of appropriate anticonvulsants or an increase in their dosages.The concomitant use of Valproic acid and Clonazepam may produce absence status. Periodic blood counts and liver function tests are advisable during long term therapy withClonazepam.The abrupt withdrawal of Clonazepam, particularly in those patients on long-term, high-dose therapy, may precipitate status epilepticus. Therefore when discontinuing Clonazepam, gradual withdrawal is essential.Clonazepam may produce an increase in salivation. This should be considered before giving the drug to patients who have difficulty handling secretions. Because of this and the possibility of respiratory depression, Clonazepam should be used with caution in patients with chronic respiratory diseases.Because of the possibility that adverse effect on physical or mental development could become apparent only after many years, a benefit-risk consideration of the long-term use ofClonazepam is important in pediatric patients.ContraindicationsClonazepam should not be used in patients with a history of sensitivity to benzodiazepine, nor in patients with clinical or biochemical evidence of significant liver disease. It may be used in patients with open angle glaucoma who are receiving appropriate therapy but is contraindicated in acute narrow angle glaucoma.Drug InteractionsThe CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors, tricyclic antidepressants and by other anticonvulsant drugs.OverdosageSymptoms of Clonazepam overdosage, like those produced by other CNS depressants, include somnolence, confusion, coma and diminished reflexes.SupplyLeptic0.5: Each box contains 10x10 tablets in AluPVC/PVDC blister strips.Leptic1 : Each box contains 5x10 tablets in Alu-PVC/PVDC blister stripsLeptic2 : Each box contains 5x10 tablets in Alu-PVC/PVDC blister strips...
Tk.6.00/=
Leptic 2 mg Tab
Leptic 2 mg TabDescriptionLeptic(Clonazepam) is available as scored tablets containing 0.5 mg, 1 mg & 2 mg Clonazepam USP. Chemically, Clonazepam is a benzodiazepine derivative. It exhibits several pharmacologic properties, which are characteristics of the benzodiazepine class of drugs. In human it is capable of suppressing the spike and wave discharge in absence seizure (petit mal) and decreasing the frequency, amplitude, duration and spread of discharge in minor motor seizure.CompositionLeptic0.5 : Each tablet contains Clonazepam USP 0.5 mg.Leptic1 : Each tablet contains Clonazepam USP 1 mg.Leptic2 : Each tablet contains Clonazepam USP 2 mg.Indications All clinical forms of epileptic disease & seizures in infants, children & adults, especially absence seizures including : atypical absence primary & secondarily generalized tonic-clonic (grand mal) tonic-clonic seizures partial (focal) seizures with elementary or complex symptomatology various forms of myoclonic seizures myoclonus & associated abnormal movements Panic disorder with or without agoraphobiaDosage and administrationInfants and children Initial dosage : 0.01 - 0.03 mg/kg/day not to exceed 0.05 mg/kg/day Increment dosage : not more than 0.25 - 0.5 mg at intervals of 3 days Maintenance dosage : 0.1-0.2 mg/kg/day Dosing interval: b.i.d./ t.i.d. Up to 1 year: 0.25 mg daily in divided dose, increase gradually to 0.5 - 1 mg. 1-5 years : 0.25 mg daily in divided dose, increase to 1-3 mg 5-12 years : 0.5 mg daily in divided dose increase to 3-6 mg. Adults and elderly Initial dosage: 1 mg daily in divided dose (Elderly 0.5 mg), not to exceed 1.5 mg/day Increment dosage : 0.5 - 1 mg at intervals of 3 days Maintenance dosage : 4 - 8 mg/day Maximum dosage : 20 mg/day should be administered with caution Dosing interval : b.i.d./t.i.d. Initial dosage should be low and increased gradually to a maintenance dosage that controls seizure without toxic effects.During discontinuation, the dosage should be tapered. Side effectsThe most frequently occurring side effects of Clonazepam are referable to CNS depression, drowsiness, fatigue, dizziness, muscle hypotonia, co-ordination disturbance, hypersalivation in infants, paradoxical aggression, irritability and mental change.Use in pregnancy and lactationThe use of Clonazepam during pregnancy or lactation should be avoided. Clonazepam is excreted into the breast milk and should therefore be avoided in breast-feeding mothers.PrecautionsWhen used in patients in whom several different types of seizure disorders co-exist, Clonazepam may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). This may require the addition of appropriate anticonvulsants or an increase in their dosages.The concomitant use of Valproic acid and Clonazepam may produce absence status. Periodic blood counts and liver function tests are advisable during long term therapy withClonazepam.The abrupt withdrawal of Clonazepam, particularly in those patients on long-term, high-dose therapy, may precipitate status epilepticus. Therefore when discontinuing Clonazepam, gradual withdrawal is essential.Clonazepam may produce an increase in salivation. This should be considered before giving the drug to patients who have difficulty handling secretions. Because of this and the possibility of respiratory depression, Clonazepam should be used with caution in patients with chronic respiratory diseases.Because of the possibility that adverse effect on physical or mental development could become apparent only after many years, a benefit-risk consideration of the long-term use ofClonazepam is important in pediatric patients.ContraindicationsClonazepam should not be used in patients with a history of sensitivity to benzodiazepine, nor in patients with clinical or biochemical evidence of significant liver disease. It may be used in patients with open angle glaucoma who are receiving appropriate therapy but is contraindicated in acute narrow angle glaucoma.Drug InteractionsThe CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors, tricyclic antidepressants and by other anticonvulsant drugs.OverdosageSymptoms of Clonazepam overdosage, like those produced by other CNS depressants, include somnolence, confusion, coma and diminished reflexes.SupplyLeptic 0.5: Each box contains 10x10 tablets in AluPVC/PVDC blister strips.Leptic1 : Each box contains 5x10 tablets in Alu-PVC/PVDC blister stripsLeptic2 : Each box contains 5x10 tablets in Alu-PVC/PVDC blister strips...
Tk.10.00/=
Migrex 200 mg Tab
Migrex 200 mg TabDescriptionTolfenamic acid (N-(2-methyl-3-chlorophenyl) anthranilic acid) belongs to the fenamate group and is a potent inhibitor of cyclo-oxygenase enzyme, thus inhibits the synthesis of important inflammatory mediators such as thromboxane (Tx) B2 and prostaglandin (PG) E2. Prostaglandins are responsible for causing swelling, pain and inflammation associated with these conditions. It acts not only by inhibiting prostaglandin synthesis, but it also has a direct antagonistic action on its receptors.Pharmacokinetic propertiesAbsorption: Readily absorbed from GI tract. Peak plasma concentration: 60-90 min. Bioavailability: 85%. Distribution: Protein-binding: 99%. Plasma half-life: 2 hr. Distributed into breast milk. Metabolism: Metabolised in the liver. Tolfenamic acid undergoes enterohepatic circulation.Excretion: Excreted in urine (90%) and faeces.IndicationsMigrex is used specifically for relieving the pain of migraine headaches and also recommended for use as an analgesic in post-operative pain, and fever.Dosage & AdministrationAcute migraine attacksAdult: 200 mg when 1st symptoms appear may be repeated once after 1-2 hr. Renal impairment: Dose adjustments may be needed. Severe: Avoid.Mild to moderate painChildren: A paediatric dosage regimen has not yet been established. Adult: 100-200 mg tid.Renal impairment: Dose adjustments may be needed. Severe: Avoid. It should be taken with food. Take water/ or immediately after meals.Preclinical safety dataThe therapeutic index for Migrex is high, and gastrointestinal ulceration and kidney changes have only been seen with oral doses approximately 6-10 times the maximum therapeutic dose recommended for tolfenamic acid.Special PrecautionsAsthma, bronchospasm, bleeding disorders, cardiovascular diseases, history of peptic ulceration, hypertension, patients with infections, liver, cardiac, or renal function impairment. Increase water intake or dose reduction to reduce dysuria. CHF; elderly; lactation.Side EffectsDysuria especially in males; diarrhoea, nausea, epigastric pain, vomiting, dyspepsia, erythema, headache. Tremor, euphoria, fatigue, pulmonary infiltration, & haematuria. Potentially Fatal: Blood dyscrasias, toxic hepatitis.PrecautionsN/AUse in Pregnancy & LactationPregnancy: This medicine is not recommended for use during pregnancy unless considered essential by your doctor. This is particularly important in the first and third trimesters. Not to be given during the third trimester of pregnancy. Lactation: In limited studies so far available, NSAIDs can appear in breast milk in very low concentrations. NSAIDs should, if possible, be avoided when breastfeeding.Drug InteractionThe rate of absorption of Migrex increases with metoclopramide and magnesium hydroxide and decreases with aluminium hydroxide. Risk of bleeding with anticoagulants and other NSAIDs increases when use with Migrex. It decreases antihypertensive response to loop diuretics, β-blockers and ACE inhibitors. Co-administration increases plasma concentrations of lithium, methotrexate and cardiac glycosides. It also increases the risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus or diuretics.Over DoseSymptoms include headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhoea, excitation, coma, drowsiness, dizziness, tinnitus, fainting, and convulsions. In cases of significant poisoning acute renal failure and liver damage are possible. Patients should be treated symptomatically as required.StorageStore in a cool, dry place, and away from direct heat and light. Keep out of the reach of children...
Tk.10.00/=
Nomi 2.5 mg tablet
Indication:Acute treatment of migraine with or without aura in adults.Dosage & Administration:The initial recommended dose is 2.5 mg. If symptoms persist or return within 24 hours, a second dose has been shown to be effective but should not be taken within 2 hours of the initial dose.Preparation:Nomi® tablet: Box containing 12 tablets in blister pack...
Tk.25.17/=
Piramed 200 mg tablet
Indication: This drug is used to treat epilepsy in both children and adults. In children it is also indicated for treatment of Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delay). It is now most frequently prescribed for the prevention of migraines. It has been used by psychiatrists to treat bipolar disorder and alcoholism. The drug is also used to treat Post Traumatic Stress Disorder. Studies suggest that Topiramate is effective against infantile spasms. Monotherapy in Epilepsy: Topiramate is indicated as initial monotherapy in patients of 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Migraine: Topiramate is indicated for adults for the prophylaxis of migraine headache...
Tk.12.00/=